TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11258785
Drug: Clindamycin (Cl)
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin (Cl) 900 mg plus aztreonam (Az) 2 g i.v. every 8 hours
Study: 3555943
Drug: Ibopamine 300
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 300 mg
Study: 3555943
Drug: Metoclopramide (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (dopamine antagonist)
Study: 3555943
Drug: Phentolamine (alpha-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (alpha-receptor antagonist) and Propranolol (beta-receptor antagonist)
Study: 31009707
Drug: Xiang-Sha-Liu-Jun-Zi tang
Normalized name: Calagel Reformulated Jun 2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiang-Sha-Liu-Jun-Zi tang (XSLJZT) 3.0 g three times daily for 28 days
Study: 20082244
Drug: Pulian Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulian Ointment (NPLO)
Study: 7954250
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide (60 mg/m2 on Days 1-3 for the first course; 60 mg/m2 on Days 1-4 for the second course; 60 mg/m2 on Days 1-5 for the third course, recycled every 3 weeks)
Study: 7954250
Drug: Intravenous vinblastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vinblastine (3 mg/m2 weekly for 3 weeks, then 6 mg/m2 every 3 weeks)
Study: 27965864
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) for depersonalisation, delivered over six sessions within a maximum of 10 weeks.
Study: 26380438
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment group (needling at Zusanli, Yanglingquan, Neiguan, Guanyuan, once per day for 6 days)
Study: 26380438
Drug: Thymosin alpha1
Normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha1 group (subdermal injection of thymosin alpha1 1.6 mg, once per day for 6 days)
Study: 26380438
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatment according to Surviving Sepsis Campaign guidelines)
Study: 23782493
Drug: Salient piece
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salient piece of candy prior to every infusion during three chemotherapy cycles
Study: 23782493
Drug: Flavorless placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavorless placebo tablets
Study: 19455176
Drug: Nutrient-enriched drink
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient-enriched drink (twice a day for 24 weeks)
Study: 19455176
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink (twice a day for 24 weeks)
Study: 16495423
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine 2.5% and prilocaine 2.5%) applied to 'IV likely' patients
Study: 2764526
Drug: Amoxicillin with
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin with probenecid
Study: 800381
Drug: Fenbufen (600-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbufen (600-800 mg/day)
Study: 800381
Drug: Fenbufen twice
Normalized name: fenbufen
DrugBank: Fenbufen (DB08981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbufen twice a day
Study: 800381
Drug: Fenbufen (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbufen (both dosing regimens)
Study: 25098377
Drug: Intensive vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive vitamin D therapy (alfacalcidiol 0.25 mcg orally with each dialysis session + ergocalciferol 50,000 IU orally once per week)
Study: 25098377
Drug: Standard vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vitamin D therapy (alfacalcidiol 0.25 mcg orally + placebo each dialysis session)
Study: 25098377
Drug: Intensive vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive vitamin D therapy
Study: 25098377
Drug: Standard vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vitamin D therapy
Study: 22743176
Drug: PPC heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPC heparin
Study: 15784148
Drug: Reference treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatment (n-propanol, 60% v/v)
Study: 12461496
Drug: Pediatricians' personal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatricians' personal treatment preferences
Study: 8603262
Drug: Dietary fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fish oil (MaxEPA 18 g/day) for 10 weeks
Study: 1759538
Drug: Interferon 5
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon 5 x 10(6) units thrice weekly for 4 months
Study: 1759538
Drug: Interferon 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon 0.25 x 10(6) U thrice weekly for 6 months (low dose)
Study: 1759538
Drug: Interferon 3
Normalized name: interferon beta-1b 0.3 MG [Betaseron]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon 3 x 10(6) U thrice weekly for 6 months (high dose)
Study: 7044649
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 mg single dose)
Study: 7044649
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg repeated doses bid)
Study: 7044649
Drug: Clonidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (1 week treatment)
Study: 7044649
Drug: Clonidine (S
Normalized name: Clonidine (substance)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (S and R doses) during dynamic physical activity (DPA)
Study: 7044649
Drug: Clonidine (S
Normalized name: Clonidine (substance)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (S and R doses) during DPA
Study: 25798575
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of statin therapy
Study: 25798575
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of statin therapy
Study: 22506302
Drug: Rockumentary music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rockumentary music therapy intervention
Study: 27487408
Drug: Recreational music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational music therapy
Study: 22506302
Drug: Rockumentary music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rockumentary music therapy
Study: 22506302
Drug: Verbal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal therapy
Study: 19150064
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg per day (A80)
Study: 19150064
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg + Ezetimibe 10 mg per day (A10E10)
Study: 7869212
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.65 ± 0.07 IU.kg‐1.wk‐1) and gonadotropin-releasing hormone analogs (66 ± 9 micrograms.kg‐1 every 28 days)
Study: 7869212
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone administered alone after interruption of gonadotropin-releasing hormone analogs
Study: 2531718
Drug: Alpha-hANP administration
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-hANP administration
Study: 3086
Drug: Complete placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete placebo (orally and by vaccine)
Study: 31628558
Drug: Pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd:YAG laser therapy (1500 J total energy, thrice/week for four weeks)
Study: 31628558
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy plus physical exercise program
Study: 22821223
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance with mandibular advancement (active group)
Study: 22821223
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance without advancement (control group)
Study: 16949482
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg clopidogrel loading dose
Study: 16949482
Drug: All clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: All clopidogrel doses
Study: 12940611
Drug: Vancomycin 15
Normalized name: vancomycin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 15 mg/kg following dialysis (Phase I)
Study: 12940611
Drug: Vancomycin 15
Normalized name: vancomycin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 15 mg/kg during the last hour of hemodialysis (Phase II)
Study: 12940611
Drug: Vancomycin 30
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin 30 mg/kg during the last 2 hours of hemodialysis (Phase III)
Study: 10852529
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (875/125 mg) administered orally 2 to 4 hours before surgery
Study: 10852529
Drug: Amoxicillin alone
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin alone (implied as a comparison)
Study: 9488196
Drug: Amlodipine (Norvasc),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (Norvasc), a third generation calcium channel blocker (CCB)
Study: 8450247
Drug: 3 MIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 MIU of systemic recombinant interferon-alpha 2a given three times weekly for 4 weeks after CO2 laser ablation
Study: 3698458
Drug: Diazepam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2 mg/kg for 15 days followed by 0.3 mg/kg for 7 days)
Study: 3698458
Drug: Oxazepam (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (0.8 mg/kg for 15 days followed by 1.2 mg/kg for 7 days)
Study: 29481695
Drug: Middle ear
Normalized name: middle ear inflation device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle ear implants (MEIs)
Study: 22273743
Drug: One-step self-etch
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step self-etch adhesive (G-Bond, GC) with low-shrinking composite (N'Durance, Septodont: N'D)
Study: 22273743
Drug: One-step self-etch
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step self-etch adhesive (G-Bond, GC) with low-shrinking composite (Kalore, GC: Ka)
Study: 22273743
Drug: One-step self-etch
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step self-etch adhesive (G-Bond, GC) with conventional composite (Z100, 3M ESPE)
Study: 16301878
Drug: Bifrontal ECT
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifrontal ECT (moderate dose, 50% above seizure threshold; n = 15)
Study: 16301878
Drug: Bitemporal ECT
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitemporal ECT (low dose, just above seizure threshold; n = 15)
Study: 16301878
Drug: Right unilateral
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right unilateral ECT (high dose, 400% above seizure threshold; n = 15)
Study: 12173784
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg (loading dose)
Study: 25633200
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream applied once every other day
Study: 25633200
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate eye drops applied thrice daily
Study: 18637604
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 mcg.kg(‐1)
Study: 16767526
Drug: Teriparatide (20-mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20-mug subcutaneous, once daily)
Study: 16767526
Drug: Antiresorptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive treatment (control group)
Study: 14633528
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion analgesia (CEA) with ropivacaine 0.2%
Study: 11104317
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (medication plus behavioral treatment)
Study: 11104317
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment alone
Study: 9116551
Drug: Prescription for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription for antibiotics for 10 days (group 1, 246 patients)
Study: 9116551
Drug: No prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prescription (group 2, 230 patients)
Study: 9116551
Drug: Prescription for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription for antibiotics if symptoms were not starting to settle after three days (group 3, 238 patients)
Study: 30463611
Drug: cALND (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: cALND (with chemotherapy)
Study: 30463611
Drug: cALND (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: cALND (before chemotherapy)
Study: 30463611
Drug: cALND (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: cALND (without chemotherapy)
Study: 18755817
Drug: Talnetant 200
Normalized name: Talnetant
DrugBank: Talnetant (DB06429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talnetant 200 mg
Study: 18487215
Drug: Oral pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentoxifylline (800 mg/day)
Study: 12482765
Drug: Isoproterenol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (20 and 40 ng.kg(‐1).min(‐1) for 15 min/dose)
Study: 10683349
Drug: Mibefradil (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (initial 50 mg daily dose uptitrated to 100 mg after 1 month, continued up to 3 years)
Study: 10683349
Drug: Placebo (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (as adjunct to usual therapy)
Study: 9332510
Drug: Fluconazole 800
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 800 mg
Study: 9332510
Drug: Prior antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior antifungal therapy failed
Study: 9332510
Drug: Fluconazole (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400-800 mg)
Study: 2944386
Drug: Acetaminophen, 1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, 1300 mg
Study: 2944386
Drug: Meclofenamate, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate, 100 mg
Study: 2944386
Drug: Meclofenamate, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate, 200 mg
Study: 31421686
Drug: Viscosupplementation (VS)
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscosupplementation (VS) treatment
Study: 24200619
Drug: FF/VI 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 100/25 mcg administered in the morning
Study: 24200619
Drug: FF/VI 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 100/25 mcg administered in the evening
Study: 24200619
Drug: FF/VI 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 100/25 mcg (morning or evening)
Study: 22367374
Drug: Emollient cream
Normalized name: EMOLLIENT CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient cream containing 0.25% zinc pyrithione
Study: 22367374
Drug: Emollient cream
Normalized name: EMOLLIENT CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient cream alone
Study: 19780002
Drug: Rescue analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue analgesic (1 mg.kg(‐1) im meperidine)
Study: 11318005
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (INO) at 1 part per million in the supine position
Study: 11318005
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of INO and prone positioning
Study: 8486508
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate as prophylactic migraine therapy
Study: 22104390
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injection added to standard treatment (eccentric-loading exercises) for 12 weeks
Study: 22104390
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (eccentric-loading exercises) alone for 12 weeks
Study: 20815273
Drug: Shenxiong Bushen
Normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenxiong Bushen Capsule (5 tablets, thrice a day)
Study: 20815273
Drug: Piracetam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (5 tablets, twice a day)
Study: 20815273
Drug: Shenxiong Bushen
Normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenxiong Bushen Capsule
Study: 15804320
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument
Study: 12445035
Drug: Omeprazole, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 120 mg day‐1 for 7 days
Study: 7274202
Drug: Zinc ammonium
Normalized name: ammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc ammonium sulfate aerosol at a nominal concentration of 20 μg/m3
Study: 7274202
Drug: Control: Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Sodium chloride aerosol at a nominal concentration of 300 μg/m3
Study: 31186401
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no compound
Study: 22695310
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg vaginal natural progesterone
Study: 20064284
Drug: UMF 20+
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMF 20+ honey (20 g)
Study: 20064284
Drug: Multiflora honey
Normalized name: Reynoutria multiflora root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiflora honey (20 g)
Study: 17378904
Drug: Iberogast (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberogast (1.1 mL)
Study: 17378904
Drug: Control (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1.1 mL)
Study: 12439764
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (c.c.HRT) with 1 mg estradiol plus 0.5 mg norethisterone acetate (NETA)
Study: 7547823
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg elemental Calcium
Study: 6996139
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of diazepam plus local anaesthetic spray
Study: 30870159
Drug: Lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1 mg/kg bolus followed by continuous infusion (48 μg · kg · min for the first hour, 24 μg · kg · min for the second hour, and 10 μg · kg · min for the next 46 hours)
Study: 25795741
Drug: Standard ground
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ground paramedic treatment
Study: 15090392
Drug: Active low-energy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low-energy extracorporeal shock wave treatment given weekly for 3 weeks
Study: 15090392
Drug: Placebo extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo extracorporeal shock wave treatment (sham)
Study: 9772598
Drug: Lappaconitine compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lappaconitine compound (12 mg lappaconitine and 22.5 mg bupivacaine)
Study: 9772598
Drug: Lappaconitine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lappaconitine (12 mg) and bupivacaine (22.5 mg)
Study: 30723735
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nutraceuticals containing 5 mg monacolin K, 200 mg Citrus bergamia, 400 mg Omega‐3, and 10 mcg trivalent chromium
Study: 30723735
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nutraceuticals containing 3 mg monacolin K, 200 mg red yeast rice, 500 mg Berberine, 0.5 mg Astaxanthin, 200 mcg folic acid, 2 mg Coenzyme Q10, and 10 mg Policosanol
Study: 22801191
Drug: Intradetrusor onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intradetrusor onabotulinumtoxinA injections (300 IU)
Study: 22801191
Drug: Suburothelial onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Suburothelial onabotulinumtoxinA injections (300 IU)
Study: 19241108
Drug: Aspirin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (low dose)
Study: 19241108
Drug: No tablets
Normalized name: caffeine Oral Tablet [No Doz]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No tablets
Study: 9849032
Drug: Chlamydia trachomatis
Normalized name: CHLAMYDIA TRACHOMATIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlamydia trachomatis antibodies
Study: 9849032
Drug: N. gonorrhoeae
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. gonorrhoeae antibodies